TNF and asthma: In the later asthma model, YCFA-33 administration significantly increased total IgG and IgG1 in serum, reduced OVA-IgE levels and IL-4 levels, decreased neutrophil content and TNF-α expression, and increased IFN-γ levels in lung lavage fluid (p<0.05).